Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: A prospective multicenter study

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Johnson, David A ^a   Barclay, Robert L ^b   Mergener, Klaus ^c   Weiss, Gunter ^d   König, Thomas ^d   Beck, Jürgen ^d   Potter, Nicholas T ^e  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Rockford Gastroenterology Associates Ltd   (United States)

^c Digestive Health Specialists   (United States)

^d EPIGENOMICS AG   (Germany)

^e Molecular Pathology Laboratory Network Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEPTIN; SEPTIN 9; UNCLASSIFIED DRUG; SEPT9 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SCREENING; COLON CANCER; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; FEMALE; HUMAN; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; INTESTINE PREPARATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCCULT BLOOD TEST; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; GENETICS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; OCCULT BLOOD; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEPTINS;

EID: 84902449237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098238     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328: 1366-1371.
3. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, et al. (2013) Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369(12): 1095-105.
4. Amri R, Bordeianou LG, Sylla P, Berger DL (2013) Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery. JAMA Surg 148: 747-754.
5. American Cancer Society (2011) Colorectal Cancer Facts and Figures 2011-2013. Atlanta: American Cancer Society.
6. Joseph DA, King JB, Miller JW, Richardson LC (2012) Prevalence of colorectal cancer screening among adults - behavioral risk factor surveillance system, United States, 2010. MMWR 61 Suppl: 51-56.
7. Klabunde CN, Joseph DA, King JB White A, Plescia M (2013) Vital Signs: Colorectal Cancer Screening Test Use - United States, 2012. MMWR 62(44): 881-888.
8. Inadomi J, Vijan S, Janz NK, Fagerlin A, Thomas JP, et al. (2012) Adherence to Colorectal Cancer Screening: A Randomized Clinical Trial of Competing Strategies. Arch of Int Med 172(7): 575-582.
9. Hoffman RM, Rhyne RL, Helitzer DL, Stone SN, Sussman AL, et al. (2011) Barriers to colorectal cancer screening: physician and general population perspectives, New Mexico, 2006. Prev Chronic Dis 8(2): 1-119.
10. Payne SR (2010) From discovery to the clinic: the novel DNA methylation biomarker mSEPT9 for the detection of colorectal cancer in blood. Epigenomics 2: 575-85.
11. Hall PA, Russell SE (2004) The pathobiology of the septin gene family. J Pathol 204: 489-505. (Pubitemid 39468160)
12. Connolly D, Abdesselam I, Verdier-Pinard P, Montagna C (2011) Septin roles in tumorigenesis. Biol Chem 392: 725-738.
13. Osaka M, Rowley JD, Zeleznik-Le NJ (1999) MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci U S A 96: 6428-6433. (Pubitemid 29256682)
14. Russell SE, McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, et al. (2000) Isolation and mapping of a human septin gene to a region on chromosome 17q commonly deleted in sporadic epithelial ovarian tumors. Cancer Res 60: 4729-4734.
15. Montagna C, Lyu MS, Hunter K, Lukes L, Lowther W, et al. (2003) The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. Cancer Res 63: 2179-2187. (Pubitemid 36538624)
16. McDade SS, Hall PA, Russell SE (2007) Translational control of SEPT9 isoforms is perturbed in disease. Hum Mol Genet 16: 742-52. (Pubitemid 47061621)
17. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J et al. (2008) DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54: 414-23. (Pubitemid 351302625)
18. Wasserkort R, Kalmar A, Valcz G, Spisak S, Krispin M, et al. (2013) Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer 13: 398.
19. Ahmed D, Danielsen SA, Aagesen TH, Bretthauer M, Thiis-Evensen E, et al. (2012) A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors. Clin Transl Gastroenterol 3: e27. doi: 10.1038/ctg.2012.21.
20. Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, et al. (2008) Sensitive detection of colorectal cancer in peripheral blood by Septin 9 DNA methylation assay. PLoS ONE 3: 1-8.
21. deVos T, Tetzner R, Model F, Weiss G, Schuster M, et al. (2009) Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal Cancer. Clin Chem 55(7): 1337-1346.
22. Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, et al. (2011) Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 9: 133. doi: 10.1186/1741-7015-9-133.
23. Tóth K, Sipos F, Kalmár A, Patai AV, Wichmann B, et al. (2012) Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS ONE 7: e46000. doi: 10.1371/journal. pone.0046000.
24. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, et al. (2014) Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63(2): 317-25.
25. Weiss G, Fassbender A, Koenig T, Tetzner R. (2012) Sensitivity of second-generation blood-based methylated Septin9 assay for early-stage colorectal cancer. J Clin Oncol 30: suppl 4; abstr 419.
26. Pepe MS (2003) The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford Statistical Science Series, Oxford University Press.
27. National Cancer Institute website. http://www.cancer.gov/cancertopics/ pdq/treatment/colon/Patient/page2 - Accessed Oct. 2013.
28. Burch JA, Soares-Weiser K, St John DJ, Duffy S, Smith S, et al. (2007) Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 14(3): 132-7. (Pubitemid 47511122)
29. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, et al. (1993) Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood. Minnesota Colon Cancer Control Study. N Engl J Med 328(19): 1365-71. (Pubitemid 23131388)
30. Holden DJ, Harris R, Porterfield DS, Jonas DE, Morgan LC, et al. (2010) Enhancing the Use and Quality of Colorectal Cancer Screening. Evidence Report/Technology Assessment No.190. AHRQ Publication No. 10-E-002. Rockville, MD: Agency for Healthcare Research and Quality.
31. Boone JD, Erickson BK, Huh WK (2010) New insights into cervical cancer screening. J Gynecol Oncol 23: 282-287.
32. Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, et al. (2012) Adverse Events after Screening and Follow-up Colonoscopy. Cancer Causes Control 23(2): 289-96.
33. Pignone M, Saha S, Hoerger T, Mandelblatt J. (2002) Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 137(2): 96-104. (Pubitemid 34779153)
34. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, et al. (2008) Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 149(9): 659-69.
35. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, et al. (2009) American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol 104(3): 739-50.
36. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, et al. (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5): 1570-95. (Pubitemid 351615355)
37. Chubak J, Bogart A, Fuller S, Laing SS, Green BB. (2013) Uptake and positive predictive value of fecal occult blood tests: A randomized controlled trial. Prev Med 57(5): 671-8.
38. Taber JM, Aspinwall LG, Heichman KA, Kinney AY. (2014) Preferences for blood-based colon cancer screening differ by race/ethnicity. Am J Health Behav 38(3): 351-61.
39. Colon Cancer Alliance website. http://www.ccalliance.org/pdf/ ColonCancerScreeningSurvey-ReportSummary.pdf. Accessed Oct. 2013.
40. Gimeno García AZ. (2012) Factors influencing colorectal cancer screening participation. Gastroenterol Res Pract: 483417.
41. Adler A, Geiger S, Keil A, Bias H, Schatz P, et al. (2012) Improving Compliance to CRC Screening by Blood and Stool Based Tests in Patients Refusing Screening Colonoscopy in Germany. UEGW. Gut 61: Suppl 3, A324.